Department of Pharmacy

Department of Pharmacy Research Pharmacometrics Publications

Denna sida på svenska

Recent publications

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Ayoun Alsoud, Rami; Svensson, Robin J.; Svensson, Elin; Gillespie, Stephen H. H. et al.

Part of Frontiers in Pharmacology, 2023.

DOI for Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development Download full text (pdf) of Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Open access
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Madathil Krishnan, Sreenath; Friberg, Lena; Mercier, Francois; Zhang, Rong et al.

Part of Clinical Pharmacology and Therapeutics, p. 851-858, 2023.

DOI for Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study Download full text (pdf) of Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Open access
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

Centanni, Maddalena; Thijs, Abel; Desar, Ingrid; Karlsson, Mats O. et al.

Part of Clinical and Translational Science, p. 73-84, 2023.

DOI for Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors Download full text (pdf) of Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

Open access
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Svensson, Robin J.; Ooi, Qing Xi; Friberg, Lena E.; Maharaj, Narendra et al.

Part of CPT, p. 154-167, 2023.

DOI for Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity Download full text (pdf) of Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Open access
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Mockeliunas, Laurynas; Faraj, Alan; Van Wijk, Rob C; Upton, Caryn M. et al.

Part of Frontiers in Pharmacology, 2023.

DOI for Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development Download full text (pdf) of Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Open access
Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Susanto, Budi O.; Svensson, Elin M.; te Brake, Lindsey; Aarnoutse, Rob E. et al.

Part of International Journal of Antimicrobial Agents, 2023.

DOI for Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin Download full text (pdf) of Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Open access
Clinical standards for the management of adverse effects during treatment for TB

Singh, K. P.; Carvalho, A. C. C.; Centis, R.; D'Ambrosio, L. et al.

Part of The International Journal of Tuberculosis and Lung Disease, p. 506-519, 2023.

DOI for Clinical standards for the management of adverse effects during treatment for TB Download full text (pdf) of Clinical standards for the management of adverse effects during treatment for TB

Open access
Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli

Bahnasawy, Salma M.; Skorup, Paul; Hanslin, Katja; Friberg, Lena et al.

Part of Cytokine, 2023.

DOI for Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli Download full text (pdf) of Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli

Open access
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Bukkems, Laura H.; Versloot, Olav; Cnossen, Marjon H.; Jönsson, Siv et al.

Part of Thrombosis and Haemostasis, p. 317-325, 2023.

DOI for Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A Download full text (pdf) of Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Open access
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Faraj, Alan; Van Wijk, Rob C; Neuman, Linda; Desai, Shraddha et al.

Part of CPT, p. 977-987, 2023.

DOI for Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy Download full text (pdf) of Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Open access
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

Faraj, Alan; Le Moan, Natacha; Gorina, Eduard; Blouse, Grant E. E. et al.

Part of Advances in Therapy, p. 3739-3750, 2023.

DOI for Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients Download full text (pdf) of Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

Open access
Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Llanos-Paez, Carolina; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 297-314, 2023.

DOI for Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials Download full text (pdf) of Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Open access
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

Van Wijk, Rob C; Lucia, Ainhoa; Sudhakar, Pavan Kumar; Sonnenkalb, Lindsay et al.

Part of iScience, 2023.

DOI for Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium Download full text (pdf) of Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

Open access
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii

Kon, Hadas; Hameir, Amichay; Nutman, Amir; Temkin, Elizabeth et al.

Part of Microbiology Spectrum, 2023.

DOI for Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii Download full text (pdf) of Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii

Open access
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

Van Wijk, Rob C; Lucia, Ainhoa; Sudhakar, Pavan Kumar; Sonnenkalb, Lindsay et al.

Part of ISCIENCE, 2023.

DOI for Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

Open access
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance

Frenk, Sammy; Temkin, Elizabeth; Lurie-Weinberger, Mor N.; Keren-Paz, Alona et al.

Part of Journal of Antimicrobial Chemotherapy, p. 934-943, 2022.

DOI for Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Grisic, Ana-Marija; Xiong, Wenyuan; Tanneau, Lénaïg; Jönsson, Siv et al.

Part of Clinical Cancer Research, p. 1363-1371, 2022.

DOI for Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab Download full text (pdf) of Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Open access
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis

Mockeliunas, Laurynas; Keutzer, Lina; Sturkenboom, Marieke G. G.; Bolhuis, Mathieu S. et al.

Part of Pharmaceutics, 2022.

DOI for Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis Download full text (pdf) of Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis

Open access
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

De Jager, Veronique; Gupte, Nikhil; Nunes, Silvia; Barnes, Grace L. et al.

Part of American Journal of Respiratory and Critical Care Medicine, p. 1228-1235, 2022.

DOI for Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections

Nutman, Amir; Temkin, Elizabeth; Lellouche, Jonathan; Rakovitsky, Nadya et al.

Part of Clinical Microbiology and Infection, p. 73-78, 2022.

DOI for In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia

Gkoufa, Aikaterini; Sou, Tomas; Karaiskos, Ilias; Routsi, Christina et al.

Part of International Journal of Antimicrobial Agents, 2022.

DOI for Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Ruth, Mike Marvin; Raaijmakers, Jelmer; van den Hombergh, Erik; Aarnoutse, Rob et al.

Part of Clinical Microbiology and Infection, p. 448.e1-448.e7, 2022.

DOI for Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics Download full text (pdf) of Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Open access
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application

Van Wijk, Rob C; Simonsson, Ulrika S. H.

Part of CPT, p. 991-1001, 2022.

DOI for Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application Download full text (pdf) of Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application

Open access
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Llanos-Paez, Carolina C.; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Part of Pharmaceutical research, p. 1779-1787, 2022.

DOI for Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients Download full text (pdf) of Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Open access
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Keutzer, Lina; You, Huifang; Farnoud, Ali; Nyberg, Joakim et al.

Part of Pharmaceutics, 2022.

DOI for Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin Download full text (pdf) of Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Open access
Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings

Minichmayr, Iris; Kappetein, Suzanne; Brill, Margreke J. E.; Friberg, Lena

Part of Antibiotics, 2022.

DOI for Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings Download full text (pdf) of Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings

Open access
A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study

Keutzer, Lina; Akhondipour, Yasamin; Forsman, Lina Davies; Simonsson, Ulrika S. H.

Part of CPT, p. 628-639, 2022.

DOI for A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study Download full text (pdf) of A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study

Open access
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance

Yin, Anyue; van Hasselt, Johan G. C.; Guchelaar, Henk-Jan; Friberg, Lena et al.

Part of Scientific Reports, 2022.

DOI for Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance Download full text (pdf) of Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance

Open access
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma

Kotani, Naoki; Dolton, Michael; Svensson, Robin J.; Ribbing, Jakob et al.

Part of Journal of clinical pharmacology, p. 905-917, 2022.

DOI for Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma Download full text (pdf) of Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma

Open access
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

Mudde, Saskia E.; Ayoun Alsoud, Rami; van der Meijden, Aart; Upton, Anna M. et al.

Part of Journal of Infectious Diseases, p. 1876-1885, 2022.

DOI for Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data Download full text (pdf) of Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data

Open access
Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue: Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations

Öbrink-Hansen, Kristina; Pham, Anh Duc; Bue, Mats; Hanberg, Pelle et al.

Part of Pharmaceutical research, p. 1633-1643, 2022.

DOI for Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue: Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections

Arrazuria, Rakel; Kerscher, Bernhard; Huber, Karen E.; Hoover, Jennifer L. et al.

Part of Frontiers in Microbiology, 2022.

DOI for Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections Download full text (pdf) of Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections

Open access
Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia

Aranzana-Climent, Vincent; Hughes, Diarmaid; Cao, Sha; Tomczak, Magdalena et al.

Part of Clinical Microbiology and Infection, p. 1367-1374, 2022.

DOI for Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia Download full text (pdf) of Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia

Open access
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose

Zhao, Chenyan; Chirkova, Anna; Rosenborg, Staffan; Palma Villar, Rodrigo et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2718-2728, 2022.

DOI for Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose Download full text (pdf) of Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose

Open access
Research priorities towards precision antibiotic therapy to improve patient care

Bulman, Zackery P.; Wicha, Sebastian G.; Nielsen, Elisabet I.; Lenhard, Justin R. et al.

Part of LANCET MICROBE, p. e795-e802, 2022.

DOI for Research priorities towards precision antibiotic therapy to improve patient care Download full text (pdf) of Research priorities towards precision antibiotic therapy to improve patient care

Open access
Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia

Dreesen, Erwin; Gijsen, Matthias; Elkayal, Omar; Annaert, Pieter et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2479-2488, 2022.

DOI for Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia
Bayesian forecasting of tumor size metrics and overall survival

Krishnan, Sreenath M.; Friberg, Lena E.

Part of CPT, p. 1604-1613, 2022.

DOI for Bayesian forecasting of tumor size metrics and overall survival Download full text (pdf) of Bayesian forecasting of tumor size metrics and overall survival

Open access
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

Faraj, Alan; Knudsen, Tom; Desai, Shraddha; Neuman, Linda et al.

Part of CPT, p. 1628-1637, 2022.

DOI for Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug Download full text (pdf) of Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

Open access
Pharmacometrics in tuberculosis: progress and opportunities

Wilkins, Justin J.; Svensson, Elin; Ernest, Jacqueline P.; Savic, Radojka M. et al.

Part of International Journal of Antimicrobial Agents, 2022.

DOI for Pharmacometrics in tuberculosis: progress and opportunities Download full text (pdf) of Pharmacometrics in tuberculosis: progress and opportunities

Open access
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects

Minichmayr, Iris; Aranzana-Climent, Vincent; Friberg, Lena

Part of International Journal of Antimicrobial Agents, 2022.

DOI for Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects Download full text (pdf) of Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects

Open access
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial

Upton, Caryn M.; Van Wijk, Rob C; Mockeliunas, Laurynas; Simonsson, Ulrika S. H. et al.

Part of eClinicalMedicine, 2022.

DOI for Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial Download full text (pdf) of Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial

Open access
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1

Sánchez, Javier; Nicolini, Valeria; Fahrni, Linda; Waldhauer, Inja et al.

Part of AAPS Journal, 2022.

DOI for Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1
Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival

Sennefelt Nyman, Sofi; Ahlström, Håkan; Dimopoulou, Angeliki; Dahlgren, David et al.

Part of BMJ Open, 2022.

DOI for Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival Download full text (pdf) of Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival

Open access
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)

Ekqvist, David; Bornefall, Anna; Augustinsson, Daniel; Sönnerbrandt, Martina et al.

Part of BMJ Open, 2022.

DOI for Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP) Download full text (pdf) of Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)

Open access
A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Germovsek, Eva; Hansson, Anna; Karlsson, Mats O.; Westin, Ake et al.

Part of Clinical Pharmacology and Therapeutics, p. 416-423, 2021.

DOI for A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Open access
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future

Rayner, Craig R.; Smith, Patrick F.; Andes, David; Andrews, Kayla et al.

Part of Clinical Pharmacology and Therapeutics, p. 867-891, 2021.

DOI for Model-Informed Drug Development for Anti-Infectives: State of the Art and Future Download full text (pdf) of Model-Informed Drug Development for Anti-Infectives: State of the Art and Future

Open access
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

Daitch, Vered; Paul, Mical; Daikos, George L.; Durante-Mangoni, Emanuele et al.

Part of BMC Infectious Diseases, 2021.

DOI for Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity Download full text (pdf) of Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

Open access
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Minichmayr, Iris K.; Karlsson, Mats O.; Jönsson, Siv

Part of Pharmaceutical research, p. 593-605, 2021.

DOI for Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety Download full text (pdf) of Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Open access
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision

Rowland Yeo, Karen; Hennig, Stefanie; Krishnaswami, Sriram; Strydom, Natasha et al.

Part of CPT, p. 649-657, 2021.

DOI for CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision Download full text (pdf) of CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision

Open access
Pivotal Role of Translation in Anti-Infective Development

Friberg, Lena E.

Part of Clinical Pharmacology and Therapeutics, p. 856-866, 2021.

DOI for Pivotal Role of Translation in Anti-Infective Development Download full text (pdf) of Pivotal Role of Translation in Anti-Infective Development

Open access